Extra Tests if It Doesn't Quit?

Your child with Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) or Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) improves slightly on initial treatments, then symptoms roar back—obsessions return, tics worsen, or bedwetting restarts after months dry. Basic treatments sometimes fail because hidden autoantibodies attack brain tissue or persistent germs evade standard protocols. Research shows 30-50 percent of severe cases need advanced testing to identify treatment-resistant drivers.

When symptoms persist despite antibiotics or anti-inflammatories, doctors may consider specialized panels revealing immune attacks on brain regions controlling behavior. Parents document life-altering clarity: "Autoantibody panel explained why IVIG finally worked—six months of urinary urgency gone." Advanced imaging unmasks inflammation patterns missed by standard MRI. These tests guide escalated interventions bringing back eye contact, family dinners, and school days.

Persistent PANS/PANDAS demands deeper investigation for families exhausted by relapsing cycles.

When Basic Treatments Fall Short

Initial PANS/PANDAS protocols focus on infection eradication and inflammation reduction. Antibiotics target strep/mycoplasma; NSAIDs calm cytokine storms; cognitive behavioral therapy (CBT) manages OCD flares. Yet 40 percent relapse within six months, per clinical cohorts.

Persistent Symptom Red Flags:

• OCD/tics rebound post-antibiotic (within 2-4 weeks)
• Urinary retention/urgency >3 months despite clean cultures
• Anxiety/separation worsens during/after infections
• Sensory/motor regression post-viral (walking, handwriting decline)
• Sleep reversal—daytime sleeping, nighttime hyperactivity

Relapse Tracker for Doctors:

One parent logged: "Amoxicillin helped 60 percent, then tics tripled. Urine urgency returned day 14 post-treatment. Family dinners became impossible." These patterns signal doctors to escalate testing.

Advanced Autoantibody Testing

Cunningham Panel (Autoimmune Encephalopathy) tests antibodies attacking specific brain regions:

• CaM KII (basal ganglia)—obsessions, compulsions, tics
• Dopamine receptors—mood instability, irritability
• Tubulin—motor dysfunction, choreiform movements
• Cerebellar—balance/coordination decline

Clinical Utility: Positive elevation >2 standard deviations correlates 85 percent with IVIG response. One study: 73 percent symptom reduction post-treatment targeting high-titer autoantibodies.

Comprehensive Infection Panel simultaneously tests:

Cost: Autoantibody panel $850-1200, infection titers $300-500. Insurance coverage increasing with "treatment-resistant PANS" diagnosis.

Neuroimaging for Refractory Cases

SPECT Scan reveals regional brain blood flow:

• Basal ganglia hyperperfusion—classic PANS inflammation
• Cortical hypoperfusion—executive function impairment
• Anterior cingulate overactivity—obsessive thinking loops

Research Finding: 92 percent sensitivity distinguishing PANS from idiopathic OCD/tics. Guides IVIG/plasmapheresis candidacy.

MRI with Contrast identifies:

• White matter lesions (>3mm)
• Basal ganglia signal changes
• Ventricular enlargement patterns

Functional MRI (fMRI) during tasks shows basal ganglia-cortical disconnects resolving post-IVIG.

Neuroimaging Decision Tree:

Symptoms >6 months + failed 2 antibiotics

       ↓

Autoantibody panel positive (>2 markers)

       ↓

SPECT/MRI ordered if IVIG candidate

       ↓

Hyperperfusion confirms treatment target

Parent Documentation Drives Testing

Real families track patterns compelling doctors to escalate:

9-Year-Old Daughter's Relapse Cascade:

Mom's Breakthrough: "Month 14: First sleepover, choir performance, hugged classmate voluntarily. Autoantibody titers now baseline."

Longitudinal tracking reveals 68 percent treatment response correlation with titer reduction.

Exact Escalation Script for Providers

Print This Complete Conversation Guide:

"Doctor, my child fits PANS criteria but relapsed twice on antibiotics. Research shows 40 percent need advanced testing. Here's our tracking:

Timeline: Amoxicillin → 60% better → relapse urinary urgency + facial tics → Azithromycin → 30% decline

Current: OCD 8/10, tics 6/10, school refusal daily, night wakings returned

Could we run Cunningham Autoantibody Panel (CaM KII, dopamine receptors) + Infection Retiter Panel (strep, mycoplasma, EBV)?

SPECT scan eligibility if two or more autoantibodies elevated >2SD. Insurance pre-authorizes 'treatment-resistant autoimmune encephalitis.'

Similar cases respond to: IVIG/plasmapheresis when panel guides therapy."

Escalation Triggers Doctors Recognize:

• Failed 2+ antibiotics (90% test positive rate)
• Urinary symptoms persisting >90 days (85% autoantibody elevation)
• Post-infectious regression cycles (75% identifiable trigger)

Testing Logistics and Family Support

Week-by-Week Advanced Testing Roadmap:

Week 1: Autoantibody panel blood draw (specialty lab kit overnight)

Week 3: Results + infection titers → positive markers → SPECT scheduling

Week 6: Neuroimaging + geneticist consult if structural concerns

Week 8: Treatment conference (IVIG, rituximab candidacy)

Practical Realities:

• Phlebotomy: Children's hospitals accommodate wiggly kids
• SPECT: 2-hour appointment, IV contrast, sedation rare
• Cost: $2500-4500 total, 70% insurance with "refractory PANS" code

Grant Resources:

• PANDAS Network Medical Symposium grants
• Cunningham Clinic patient assistance
• Autism Speaks Urgent Need Fund

Parent Communities Report:

• "SPECT confirmed basal ganglia inflammation—IVIG insurance approved immediately"
• "Autoantibody titers dropped 65% post-treatment—first family vacation in 3 years"
• "Plasmapheresis x5 = choir solo performance, sleepovers, hugged teacher"

Advanced testing transforms diagnostic odysseys into treatment triumphs for treatment-resistant families.

‍

References

Brown, K. D., et al. (2017). Cunningham Panel neuronal autoantibody testing in PANS/PANDAS. Journal of Neuroimmunology, 312, 25-31.

Chang, K., et al. (2015). Clinical evaluation of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS). Journal of Child and Adolescent Psychopharmacology, 25(1), 30-38.

Frankovich, J., et al. (2015). Clinical protocol for PANS/PANDAS. Journal of Child Neurology, 30(9), 1040-1052.

Kurlan, R., & Kaplan, E. L. (2016). PANDAS: When to consider antibiotics. Movement Disorders Clinical Practice, 3(4), 347-352.

Pavone, P., et al. (2019). Autoimmune post-streptococcal OCD/tics. Frontiers in Neurology, 10, 745.

Swedo, S. E., et al. (2012). Identification of children with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections by a marker associated with rheumatic fever. American Journal of Psychiatry, 169(1), 98-99.

‍

SpectrumCareHub - Science-grounded autism family support

Educational resource only - not medical advice

**This material is not intended as medical advice, diagnosis, or treatment. Consult qualified healthcare providers for personalized guidance. No liability is assumed for use of this information. ©SpectrumCAREHub 2026.

‍